Rosaria Anna Fontanella, Puja Ghosh, Ada Pesapane, Fatemeh Taktaz, Armando Puocci, Martina Franzese, Maria Federica Feliciano, Giovanni Tortorella, Lucia Scisciola, Eduardo Sommella, Concetta Ambrosino, Giuseppe Paolisso, Michelangela Barbieri
BACKGROUND: Several evidence demonstrated that glucagon-like peptide 1 receptor agonists (GLP1-RAs) reduce the risk of dementia in type 2 diabetes patients by improving memory, learning, and overcoming cognitive impairment. In this study, we elucidated the molecular processes underlying the protective effect of Tirzepatide (TIR), a dual glucose-dependent insulinotropic polypeptide receptor agonist (GIP-RA)/ GLP-1RA, against learning and memory disorders. METHODS: We investigated the effects of TIR on markers of neuronal growth (CREB and BDNF), apoptosis (BAX/Bcl2 ratio) differentiation (pAkt, MAP2, GAP43, and AGBL4), and insulin resistance (GLUT1, GLUT4, GLUT3 and SORBS1) in a neuroblastoma cell line (SHSY5Y) exposed to normal and high glucose concentration...
January 29, 2024: Journal of Translational Medicine